CORLIFE
Desconocido
ARISE: Aortic Valve Replacement using Individualised Regenerative Allografts Bridging the Therapeutic Gap
CORLIFE OHG
participó en un
H2020:
H2020-PHC-2014-2015
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. In affected...
2014-12-01 - 2019-03-31 | Financiado
2014-12-01 - 2019-03-31 | Financiado
ESPOIR: European clinical study for the application of regenerative heart valves
CORLIFE OHG
participó en un
FP7:
Acquired and congenital heart disease can necessitate heart valve replacement. However, current heart valve substitutes are not considered i...
Financiado
Financiado
TECAS: Towards Tissue Engineering Solutions for Cardiovascular Surgery
CORLIFE OHG
participó en un
FP7:
The aim of the TECAS ITN is to integrate the major European contributors in the field of cardiovascular tissue engineering (TE) and regenera...
Financiado
Financiado
* No se disponen de datos de la empresa actual.